Sponsored

Pembrolizumab Plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.

0 comments

Leave a Reply

Log In

New to CTSNet? Sign Up